Jim Simons’s Rocket Pharmaceuticals RCKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.28M Buy
637,174
+216,000
+51% +$858K ﹤0.01% 1834
2025
Q4
$1.48M Buy
421,174
+283,997
+207% +$972K ﹤0.01% 2055
2025
Q3
$447K Sell
137,177
-324,197
-70% -$1.02M ﹤0.01% 2846
2025
Q2
$1.13M Buy
461,374
+122,900
+36% +$623K ﹤0.01% 2449
2025
Q1
$2.26M Buy
338,474
+119,955
+55% +$1.19M ﹤0.01% 1924
2024
Q4
$2.75M Buy
+218,519
New +$3.29M ﹤0.01% 1839
2024
Q3
Sell
-99,574
Closed -$2.14M 3815
2024
Q2
$2.14M Buy
+99,574
New +$2.29M ﹤0.01% 1844
2024
Q1
Sell
-62,674
Closed -$1.88M 4003
2023
Q4
$1.88M Sell
62,674
-130,800
-68% -$2.89M ﹤0.01% 1988
2023
Q3
$3.96M Buy
193,474
+164,600
+570% +$2.99M 0.01% 1433
2023
Q2
$574K Sell
28,874
-84,500
-75% -$1.71M ﹤0.01% 2800
2023
Q1
$1.94M Sell
113,374
-45,426
-29% -$889K ﹤0.01% 2049
2022
Q4
$3.11M Sell
158,800
-321,000
-67% -$5.91M ﹤0.01% 1793
2022
Q3
$7.66M Buy
479,800
+45,900
+11% +$716K 0.01% 1171
2022
Q2
$5.97M Buy
433,900
+277,400
+177% +$3.31M 0.01% 1432
2022
Q1
$2.48M Buy
156,500
+4,701
+3% +$81.2K ﹤0.01% 2068
2021
Q4
$3.31M Buy
151,799
+36,306
+31% +$990K ﹤0.01% 1793
2021
Q3
$3.45M Buy
115,493
+95,393
+475% +$3.47M ﹤0.01% 1690
2021
Q2
$890K Sell
20,100
-35,490
-64% -$1.54M ﹤0.01% 2724
2021
Q1
$2.47M Buy
+55,590
New +$3.05M ﹤0.01% 2086
2020
Q2
Sell
-93,600
Closed -$1.31M 3707
2020
Q1
$1.31M Buy
+93,600
New +$1.85M ﹤0.01% 2288
2019
Q4
Sell
-27,900
Closed -$325K 3702
2019
Q3
$325K Buy
+27,900
New +$346K ﹤0.01% 3013
2019
Q2
Sell
-17,301
Closed -$303K 3720
2019
Q1
$303K Sell
17,301
-18,517
-52% -$292K ﹤0.01% 3091
2018
Q4
$531K Sell
35,818
-31,007
-46% -$515K ﹤0.01% 2847
2018
Q3
$1.65M Sell
66,825
-196,820
-75% -$4.27M ﹤0.01% 2376
2018
Q2
$5.17M Buy
263,645
+95,970
+57% +$1.82M 0.01% 1771
2018
Q1
$3.14M Buy
+167,675
New +$2.73M ﹤0.01% 2081

Other funds holding RCKT

Jim Simons's RCKT Position: Q1 2026 in Review

Jim Simons increased its Rocket Pharmaceuticals (RCKT) stake by 51% in Q1 2026, buying an estimated $858K and bringing the position to 637,174 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

Jim Simons first reported a position in RCKT in Q1 2018 and has held it in 26 quarters since. The position peaked at $7.66M in Q3 2022. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Jim Simons held 637,174 shares of Rocket Pharmaceuticals worth $2.28M as of Q1 2026.
  • Jim Simons bought 216,000 Rocket Pharmaceuticals shares in Q1 2026, an estimated $858K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1834 holding.
  • Jim Simons first reported a position in Rocket Pharmaceuticals in Q1 2018 and has held it in 26 quarters since.
  • Jim Simons's Rocket Pharmaceuticals position peaked at $7.66M in Q3 2022.
  • 199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.